Efficacy Of Gonadotropin‐Releasing Hormone Agonist (Buserelin) in The Treatment Of Endometriosis

L Rönnberg, Lars Rönnberg, Aarne I. Koskimies, A Koskimies, Timo Laatikainen, T Laatikainen, TAPIO RANTA, T Ranta, J Saastamoinen
Acta obstetricia et gynecologica Scandinavica · 1989 · vol. 68(1) , pp. 49–53 · doi:10.3109/00016348909087689 · PMID:2508418 · W2123399607
article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Buserelin treatment for 6 months reduced endometriosis scores by 82.2%, resolved associated symptoms, and resulted in pregnancy in over half of desiring patients with minimal side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

In a multicenter study, the efficacy of and tolerance of 6 months' intranasal gonadotropin-releasing hormone agonist (buserelin) treatment (300 micrograms x 3/day) on laparoscopically verified endometriosis was evaluated in 25 patients. At second-look laparoscopy at the end of medication, the mean endometriosis score had fallen by 82.2%. All endometriosis-associated symptoms and physical findings decreased or almost disappeared during buserelin administration. After discontinuing therapy, they showed a tendency to reappear, but nevertheless they were milder after one year of follow-up, than before treatment. Seven (54%) of the 13 women wishing pregnancy actually conceived. Vaginal irregular spotting bleedings during the first 2 months occurred in 7 patients. No patient withdrew from the trial because of side effects, although almost all women developed symptoms of estrogen deficiency (serum estradiol concentrations fell to menopausal levels).

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Endometriosis Pregnancy Administration, Intranasal Adult Buserelin Buserelin Clinical Trials as Topic Endometriosis Endometriosis Endometriosis Female Follow-Up Studies Hormones Hormones Humans Multicenter Studies as Topic

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (12)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:15.954262+00:00
License: CC0 · commercial use OK